Trimeris Inc.
2530 Meridian Parkway
2nd Floor
Durham,
NC 27713
United States - Map
Phone: 919-806-4682
Fax: 919-806-4770
Web Site: http://www.trimeris.com
| Trimeris, Inc., a biopharmaceutical company, engages primarily in the commercialization of a class of fusion inhibitors for antiviral drug treatments. Its fusion inhibitors impair viral fusion, a complex process by which viruses attach to, penetrate, and infect host cells. The company offers FUZEON, a human immunodeficiency virus (HIV) fusion inhibitor and a 36-amino acid synthetic peptide that binds to a key region of an HIV surface protein called gp41 under a collaboration with F. Hoffmann-La Roche Ltd. Its FUZEON inhibitor blocks HIV viral fusion by interfering with certain structural rearrangements within gp41 that are required for HIV to fuse to and enter a host cell. FUZEON is approved in the United States, Canada, and the European Union. The company also holds TRI-1144, a next generation fusion inhibitor candidate that completed Phase I clinical trials. Trimeris, Inc. was founded in 1993 and is based in Durham, North Carolina. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Martin A. Mattingly Pharm.D., 52
Chief Exec. Officer, Pres and Director |
$
616.00K |
$
0 | Mr. Andrew L. Graham CPA, 39
Chief Financial Officer, Principal Accounting Officer, Director of Fin. and Sec. |
$
245.00K |
$
0 | Mr. Michael A. Alrutz J.D., Ph.D, 39
Gen. Counsel |
$
245.00K |
$
0 | Dr. M. Lynn Smiley M.D., 56
Sr. VP of Regulatory Affairs Compliance & Drug Safety |
N/A
| N/A | Dr. George Koszalka Ph.D., 58
Exec. VP of Scientific Operations |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
0.03 (0.91%) 
Profile
